

Oklahoma Health Care Authority

Drug Utilization Review Board (DUR Board)

Meeting – April 8, 2015 @ 4:00 p.m.

Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call To Order

- A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

- A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. March 11, 2015 DUR Minutes – Vote
- B. March 11, 2015 DUR Recommendations Memorandum

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

4. Update on Medication Coverage Authorization Unit/Oral Viscous Lidocaine Claims Analysis Update – See Appendix B

- A. Medication Coverage Activity for March 2015
- B. Pharmacy Help Desk Activity for March 2015
- C. Oral Viscous Lidocaine Claims Analysis Update

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

5. Fiscal Year 2014 Annual Review of SoonerCare Pharmacy Benefit – See Appendix C

- A. Introduction
- B. Total Enrollment
- C. Traditional Versus Specialty Pharmacy Products
- D. Top 10 Therapeutic Classes by Reimbursement
- E. Hepatitis C Drug Spending
- F. Generic Medication Price Increases
- G. Conclusion
- H. Top 100 Reimbursed Drugs by Fiscal Year
- I. Top 50 Medications by Total Number of Claims
- J. Top Traditional Therapeutic Classes by Fiscal Year
- K. Top Specialty Therapeutic Classes by Fiscal Year

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Sylvant™ (Siltuximab) – See Appendix D

- A. College of Pharmacy Recommendations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

- 7. Action Item – Vote to Prior Authorize Ecoza™ (Econazole Nitrate), Jublia® (Efinaconazole), and Kerydin™ (Tavaborole) – See Appendix E**
A. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

- 8. Action Item – Vote to Prior Authorize Izba® (Travoprost Ophthalmic Solution) – See Appendix F**
A. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

- 9. Annual Review of Antihypertensive Medications and 30-Day Notice to Prior Authorize Hemangeol™ (Propranolol Oral Solution), Sotylize™ (Sotalol Oral Solution), and Prestalia® (Perindopril/Amlodipine) – See Appendix G**
A. Current Prior Authorization Criteria
B. Utilization of Antihypertensive Medications
C. Prior Authorization of Antihypertensive Medications
D. Market News and Updates
E. Product Summaries
F. College of Pharmacy Recommendations
G. Utilization Details of Antihypertensive Medications

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

- 10. Annual Review of Hereditary Angioedema Medications and 30-Day Notice to Prior Authorize Ruconest® (C1 Esterase Inhibitor) – See Appendix H**
A. Current Prior Authorization Criteria
B. Utilization of Hereditary Angioedema Medications
C. Prior Authorization of Hereditary Angioedema Medications
D. Market News and Updates
E. Ruconest® (C1 Esterase Inhibitor) Product Summary
F. College of Pharmacy Recommendations
G. Utilization Details of Hereditary Angioedema Medications

Items to be presented by Dr. Anderson, Dr. Muchmore, Chairman:

- 11. Annual Review of Diabetes Medications and 30-Day Notice to Prior Authorize Tanzeum™ (Albiglutide), Trulicity™ (Dulaglutide), Cycloset® (Bromocriptine), Jardiance® (Empagliflozin), Invokamet™ (Canagliflozin/Metformin), Xigduo™ XR (Dapagliflozin/Metformin Extended-Release), Glyxambi® (Empagliflozin/Linagliptin), Afrezza® (Insulin Human Inhalation Powder), and Toujeo® (Insulin Glargine) – See Appendix I**
A. Current Prior Authorization Criteria
B. Utilization of Diabetes Medications
C. Prior Authorization of Diabetes Medications
D. Market News and Updates
E. Product Summaries
F. College of Pharmacy Recommendations
G. Utilization Details of Diabetic Medications

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

12. Annual Review of Pediculicides – See Appendix J

- A. Current Prior Authorization Criteria
- B. Utilization of Pediculicides
- C. Prior Authorization of Pediculicides
- D. Market News and Updates
- E. Summary of Pediculicide Mailing
- F. College of Pharmacy Recommendations
- G. Utilization Details of Pediculicides

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

13. FDA and DEA Updates – See Appendix K

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

14. Future Business

- A. Annual Reviews
- B. New Product Reviews

Items to be presented by Dr. Muchmore, Chairman:

15. Adjournment